Xcout Intel
Haya Therapeutics SA
HAYA Therapeutics is a precision medicines company developing RNA-guided therapeutics to target regulatory genomic dark matter for serious diseases. The company maintains dual roots with headquarters in Lausanne, Switzerland and a U.S. location in San Diego, California. It operates as a privately held biotech innovator.
Subscribe to see Haya Therapeutics SA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Haya Therapeutics SA at a glance
Haya Therapeutics SA is a biotechnology company headquartered in Switzerland. It has raised at least $90M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in May 2025. Xcout tracks 11 named people at Haya Therapeutics SA, including Eric Adam (Chief Operating Officer (COO)).
Haya Therapeutics SA leadership
- Eric AdamChief Operating Officer (COO)
- Jérôme AndriesChief Financial Officer (CFO)
- Jordan ShinChief Medical Officer (CMO)
- Richard LawChief Business Officer (CBO)
- Brian ThomasChairman
- Samir OunzainChief Executive Officer (CEO) & co-founder
5 more named people on record for Haya Therapeutics SA, with roles, board committees and tenure — see the full roster →
Haya Therapeutics SA funding rounds
At least $90M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 12 named | |
| Series A | $25M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Haya Therapeutics SA competitors
A few of Haya Therapeutics SA's closest competitors — see the full list of competitors and alternatives →
Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, that develops next-generation precision medicines.
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Iris Medicine is an early-stage life sciences and biotechnology company pioneering allele-selective RNA therapies. Headquartered in California, the company develops novel treatments utilizing its proprietary sbRNA technology platform.
Nerai Bioscience AG is a biotechnology company headquartered in Zurich, Switzerland, that is focused on redefining genetic medicine.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Get Haya Therapeutics SA's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Haya Therapeutics SA in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access